Free tool
FAERS Monitor: Ebglyss
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761306 or its brand name (Ebglyss, Lebrikizumab-Lbkz). Reports on generic versions are filed under their own applications.
Reports
2,280
Serious
254
11% of reports
Hospitalization
66
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus264
- injection site pain260
- drug ineffective241
- rash178
- conjunctivitis154
- dermatitis atopic149
- eczema135
- erythema109
- dry skin79
- incorrect dose administered72
- ocular hyperaemia62
- skin exfoliation62
- urticaria61
- condition aggravated56
- eye pruritus52
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 71 |
| 2025 | 1,020 |
| 2026 | 1,181 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,879 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| conjunctivitisSignal | 154 | 77.2 | 66.2 | 11,424 |
| dermatitis atopicSignal | 149 | 26.1 | 22.4 | 3,576 |
| eczemaSignal | 135 | 23.9 | 20.3 | 2,933 |
| eye pruritusSignal | 52 | 14.3 | 10.9 | 630 |
| ocular hyperaemiaSignal | 62 | 12.1 | 9.4 | 619 |
| injection site painSignal | 260 | 7.8 | 7.0 | 1,562 |
| skin exfoliationSignal | 62 | 6.8 | 5.3 | 301 |
| pruritusSignal | 264 | 6.3 | 5.7 | 1,203 |
| dry skinSignal | 79 | 5.5 | 4.4 | 285 |
| erythemaSignal | 109 | 4.9 | 4.1 | 337 |
| rashSignal | 178 | 3.8 | 3.3 | 367 |
| urticariaSignal | 61 | 3.4 | 2.6 | 100 |
| incorrect dose administeredSignal | 72 | 2.9 | 2.3 | 89 |
| condition aggravated | 56 | 1.7 | 1.3 | 16 |
| drug ineffective | 241 | 1.7 | 1.5 | 71 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.